BioSpace News Archive

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, and Solar Therapeutics (Solar), America’s only energy-independent cannabis dispensary, announced today that the companies’ collaborative LED implementation yielded more than $1 million in total rebates from National Grid, Solar’s local utility provider.

Babson Diagnostics (Babson), a transformative medical technology company improving customer access to diagnostic blood testing, was named one of Fierce Medtech’s elite “Fierce 15.”

Medical Diagnostic Laboratories, L.L.C., (MDL) , member of Genesis Biotechnology Group ® (GBG) and CLIA-certified, CAP-accredited laboratory specializing in high-complexity, state-of-the-art, automated DNA-based molecular analyses, launched a new line of testing for the field of Urology.

A person with glaucoma can lose as much as 40 per cent of their sight without noticeable symptoms and it is the leading cause of irreversible blindness that affects 78 million people worldwide, including over 800,000 Canadians, half of whom don’t even know they have it, according to the Canadian Ophthalmological Society.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam,

Sorrento Therapeutics, Inc. announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai.

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce a service agreement with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.

Medolife Rx, Inc. (“Medolife”), a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today preclinical trial results on its lead drug candidate Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions,

Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical site-centric technologies, today announced that it has acquired Bio-Optronics, maker of CCTrialSuite - which includes Clinical Conductor, the leading clinical trial management system (CTMS) for health systems and research sites,

Genome and Company (KOSDAQ: 314130), a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA, Darmstadt, Germany and Pfizer Inc. with the aim of developing the world’s first immuno-oncology microbiome therapeutic